Publications en collaboration avec des chercheurs de Hospital Universitario La Paz (28)

2024

  1. Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: data from the Spanish society of rheumathology Lupus Register (RELESSER)

    Rheumatology International, Vol. 44, Núm. 11, pp. 2445-2455

  2. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

2021

  1. HLA association with the susceptibility to anti-synthetase syndrome

    Joint Bone Spine, Vol. 88, Núm. 3

  2. Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?

    Rheumatology (Oxford, England), Vol. 60, Núm. 11, pp. 5329-5336

  3. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 4, pp. 657-662

  2. Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry)

    Lupus, Vol. 29, Núm. 1, pp. 27-36

  3. Expert Recommendations on the Interleukin 6 Blockade in Patients with Rheumatoid Arthritis

    Reumatologia Clinica, Vol. 16, Núm. 4, pp. 272-281

  4. Hormonal Dependence and Cancer in Systemic Lupus Erythematosus

    Arthritis Care and Research, Vol. 72, Núm. 2, pp. 216-224

  5. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: Data from the RELESSER Registry

    Rheumatology (United Kingdom), Vol. 59, Núm. 8, pp. 2043-2051

  6. Influence of MUC5B gene on antisynthetase syndrome

    Scientific Reports, Vol. 10, Núm. 1

  7. Practical Aspects of Biological Throught Levels and Antidrug Antibodies in Rheumatoid Arthritis and Spondyloarthritis

    Reumatologia Clinica, Vol. 16, Núm. 5, pp. 378-385

2019

  1. Budget impact analysis of subcutaneous belimumab in patients with systemic lupus erythematosus in Spain

    ClinicoEconomics and Outcomes Research, Vol. 11, pp. 757-765

  2. LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients

    Rheumatology International, Vol. 39, Núm. 11, pp. 1875-1882

  3. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial

    Arthritis and Rheumatology, Vol. 71, Núm. 10, pp. 1616-1625

  4. Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 48, Núm. 6, pp. 1025-1029

2018

  1. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients

    Seminars in Arthritis and Rheumatism, Vol. 48, Núm. 1, pp. 22-27

  2. Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review

    Rheumatology International, Vol. 38, Núm. 6, pp. 975-983

2017

  1. Disease Activity As a Major Determinant of Quality of Life and Physical Function in Patients With Early Axial Spondyloarthritis

    Arthritis Care and Research, Vol. 69, Núm. 1, pp. 150-155